Transactions
The below tombstones represent a select set of the transactions which JSB-Partners has advised on:
- Partnering of
- 2 FDA Approved Assets with
- $430,000,000
- Advising Shareholders
- In Sale to
- $320,000,000
- Partnering of
- Phase 1 APN01 to
- €252,000,000
- Partnering of
- Phase 2 Fipamezole with
- $212,000,000
- Partnering of
- Phase 3 safinamide with
- $200,000,000
- Sale of
- to
- $189,000,000
- Partnering of
- Pre-Clinical CRB-15 with
- $90,000,000
- Partnering of
- Phase 3 Desmoteplase with
- $69,500,000
- Sale of
- Pre-Clinical Oncology Program to
- $67,000,000
- Partnering of ex-US rights
- Phase 3 Desmoteplase with
- €65,000,000
- Partnering of
- Phase 2 P93/01 with
- $35,000,000
- Raised Series F
Preferred Stock 
- $30,000,000
- Sale of
- to
- €28,000,000
- Partnering of
- Phase 3 safinamide with
- €20,000,000
- Raised Series C
Private Placement 
- €16,000,000